Luminary's CAR-T Therapies
Disruptive. Lucrative. Rich with potential.
Our therapies will disrupt established commercial markets (i.e., Non-Hodgkin Lymphoma therapies) and develop new untapped markets for autoimmune disease (i.e., Systematic Scleroderma using CAR-T therapies). The revenue potential is impressive.
BAFF CAR-T Market Potential
Non-Hodgkin Lymphoma – $50M
Systematic Scleroderma – $340M
Non-Hodgkin Lymphoma – 3rd line treatment
- Established $1B commercial market today
- ~25% of patients relapse due to Antigen Escape
- 5% market share = $50M in revenue potential
Systematic Scleroderma
- Currently no curative treatment – TAM of ~10,000 patients per year
- 10% market share = $340M in revenue potential
